Journal of Clinical Oncology & Advanced Therapy

Abstract

Background: Glioblastoma (GBM) is a highly lethal, therapy-resistant malignancy characterized by angi ogenesis and dysregulated EGFR/VEGFR2 signaling. AminoTriComplex (ATC) is a standardized botanical formulation containing twelve bioactive components with known anti-angiogenic and pro-apoptotic proper ties.

Objective: To evaluate the anti-GBM activity of ATC in vitro and in vivo, and to report a clinical case demon strating biochemical and radiologic response during ATC therapy.

Methods: Human GBM cell lines (U251 and U-87 MG) and xenograft models were treated with ATC. Cell viability, apoptosis, migration/invasion, and molecular signaling (EGFR, p-AKT, p-ERK, p-STAT3, Beclin-1, LC3-II) were measured. A 29-year-old male with recurrent, multi-resistant GBM received ATC (3 capsules TID for 3 months); serum/plasma biomarkers and MRI changes were monitored.

Results: ATC reduced cell viability (IC₅₀≈28 µM), induced >45% apoptosis (Annexin V/PI assay), down-reg ulated Bcl-2 (-70%) and up-regulated Bax (+240%), suppressed p-AKT/p-ERK/p-STAT3, and enhanced Be clin-1 and LC3-II expression. In xenografts, tumor volume decreased ≈70% and CD31⁺ density ≈65%. Clin ically, YKL-40 (18×→4×), MMP-9 (56×→8×), VEGF (28×→6×), and IL-8 (11×→3×) fell markedly, with radiographic necrosis and regression of enhancing lesions.

Conclusion: ATC demonstrates multimodal anti-GBM effects through angiogenesis inhibition, EGFR/STAT3 suppression, and pro-apoptotic/autophagic activation. These findings justify further controlled clinical inves tigation.